NASDAQ:LYEL Lyell Immunopharma (LYEL) Stock Price, News & Analysis $15.83 -1.03 (-6.11%) As of 01:45 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Lyell Immunopharma Stock (NASDAQ:LYEL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Lyell Immunopharma alerts:Sign Up Key Stats Today's Range$15.54▼$16.8650-Day Range$7.51▼$16.8652-Week Range$7.20▼$45.00Volume54,206 shsAverage Volume141,764 shsMarket Capitalization$389.20 millionP/E RatioN/ADividend YieldN/APrice Target$40.86Consensus RatingModerate Buy Company Overview Lyell Immunopharma is a clinical-stage biotechnology company developing engineered T-cell therapies for people with cancer, with a focus on solid tumors. Its research aims to improve T cells’ ability to recognize and attack cancer cells and to remain active in the challenging environment inside tumors. The company’s investigational programs have included CAR T-cell and tumor-infiltrating lymphocyte (TIL) therapies. These approaches use a patient’s own immune cells, which are modified or selected and expanded before being administered as a potential treatment. Lyell’s candidates have been studied in clinical trials for cancers including breast cancer, lung cancer and melanoma; they are investigational and are not approved treatments. Founded in 2018, Lyell is based in South San Francisco, California. Its work centers on research and clinical development, including studies conducted in the United States. The company’s programs and priorities may change as clinical results and development plans evolve.AI Generated. May Contain Errors. Read More Lyell Immunopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks72nd Percentile Overall ScoreLYEL MarketRank™: 3.60460552139 of 5 starsLyell Immunopharma scored higher than 72% of companies evaluated by MarketBeat, and ranked 193rd out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingModerate Buy Consensus RatingLyell Immunopharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 1 strong buy rating, 6 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialLyell Immunopharma has a consensus price target of $40.86, representing about 154.4% upside from its current price of $16.06.Amount of Analyst CoverageLyell Immunopharma has only been the subject of 4 research reports in the past 90 days.Read more about Lyell Immunopharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Lyell Immunopharma are expected to decrease in the coming year, from ($7.16) to ($7.21) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lyell Immunopharma is -1.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lyell Immunopharma is -1.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLyell Immunopharma has a P/B Ratio of 2.05. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.11% of the float of Lyell Immunopharma has been sold short.Short Interest Ratio / Days to CoverLyell Immunopharma has a short interest ratio ("days to cover") of 10.43, which indicates bearish sentiment.Change versus previous monthShort interest in Lyell Immunopharma has recently increased by 0.81%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLyell Immunopharma does not currently pay a dividend.Dividend GrowthLyell Immunopharma does not have a long track record of dividend growth. News and Social Media4.3 / 5News Sentiment0.94 News SentimentLyell Immunopharma has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Lyell Immunopharma this week, compared to 2 articles on an average week.Search Interest2 people have searched for LYEL on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Lyell Immunopharma to their MarketBeat watchlist in the last 30 days. Company Ownership4.5 / 5Insider TradingAcquiring Shares Cluster Insider Buying2 insiders have purchased shares of Lyell Immunopharma in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $49,989,991.00 in company stock, which represents 12.6620% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Lyell Immunopharma insiders have bought 500,300.15% more of their company's stock than they have sold. Specifically, they have bought $49,999,983.00 in company stock and sold $9,992.00 in company stock.Percentage Held by Insiders6.20% of the stock of Lyell Immunopharma is held by insiders.Percentage Held by Institutions66.05% of the stock of Lyell Immunopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Lyell Immunopharma's insider trading history. Receive LYEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lyell Immunopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LYEL Stock News HeadlinesLyell Immunopharma, Inc. (LYEL) Presents at Stifel 2026 Healthcare Conference 2026 TranscriptNovember 11 at 3:17 PM | seekingalpha.comLyell Immunopharma (NASDAQ:LYEL) Major Shareholder Acquires $24,999,991.74 in StockNovember 8, 2026 | americanbankingnews.comYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.November 12 at 1:00 AM | Profits Run (Ad)Lyell Immunopharma (NASDAQ:LYEL) Stock: Insider Venture Fund Xiii L.P. Arch Purchases 2,321,262 SharesNovember 6, 2026 | insidertrades.comLyell: Upgrade To 'Buy' On Ronde-Cel Advancement LBCL And $80 Million Funding BoostNovember 5, 2026 | seekingalpha.comLyell Immunopharma (NASDAQ:LYEL) Earns "Buy" Rating from Needham & Company LLCNovember 5, 2026 | americanbankingnews.comLyell Immunopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 5, 2026 | marketscreener.comMLyell Immunopharma, Inc. announced that it expects to receive $79.999991 million in fundingNovember 4, 2026 | marketscreener.comMSee More Headlines LYEL Stock Analysis - Frequently Asked Questions How have LYEL shares performed this year? Lyell Immunopharma's stock was trading at $30.78 at the start of the year. Since then, LYEL stock has decreased by 47.8% and is now trading at $16.0580. How were Lyell Immunopharma's earnings last quarter? Lyell Immunopharma, Inc. (NASDAQ:LYEL) issued its quarterly earnings results on Wednesday, November, 4th. The company reported ($1.86) EPS for the quarter, topping analysts' consensus estimates of ($2.01) by $0.15. The firm had revenue of $3 thousand for the quarter, compared to analysts' expectations of $4 thousand. Lyell Immunopharma had a negative trailing twelve-month return on equity of 107.62% and a negative net margin of 1,701,066.75%. When did Lyell Immunopharma's stock split? Shares of Lyell Immunopharma reverse split on the morning of Friday, May 30th 2025.The 1-20 reverse split was announced on Friday, May 30th 2025. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 30th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Lyell Immunopharma IPO? Lyell Immunopharma (LYEL) raised $425 million in an initial public offering on Tuesday, June 15th 2021. The company issued 25,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, BofA Securities, J.P. Morgan and Morgan Stanley served as the underwriters for the IPO. Who are Lyell Immunopharma's major shareholders? Top institutional shareholders of Lyell Immunopharma include State Street Corp (0.78%), Allspring Global Investments Holdings LLC (0.07%) and Ieq Capital LLC (0.04%). Insiders that own company stock include Venture Fund Xiii LP Arch, Arch Venture Partners Ix, Llc, Lynn Seely, Lynn Seely, Richard Klausner, Richard Klausner, David Shook, Jarrad Mattieu Aguirre, Stephen J Hill, Gary K Lee, Veronica Sanchez Bulis, Sumant Ramachandra, Charles W Newton, Charles W Newton, Otis W Brawley and Otis W Brawley. View institutional ownership trends. How do I buy shares of Lyell Immunopharma? Shares of LYEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Lyell Immunopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lyell Immunopharma investors own include NVIDIA (NVDA), SoFi Technologies (SOFI), fuboTV (FUBO), Acumen Pharmaceuticals (ABOS), Allogene Therapeutics (ALLO), Advanced Micro Devices (AMD) and argenex (ARGX). Company Calendar Last Earnings11/04/2026Today11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 8 days, LYEL's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:LYEL CIK1806952 Webwww.lyell.com Phone650-695-0677FaxN/AEmployees161Year Founded2018Price Target and Rating Average Price Target for Lyell Immunopharma$40.86 High Price Target$49.00 Low Price Target$34.00 Potential Upside/Downside+157.9%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($12.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$274.45 million Net Margins-1,701,066.75% Pretax Margin-1,701,066.62% Return on Equity-107.62% Return on Assets-80.01% Debt Debt-to-Equity RatioN/A Current Ratio4.02 Quick Ratio4.02 Sales & Book Value Annual Sales$15 thousand Price / Sales25,962.82 Cash FlowN/A Price / Cash FlowN/A Book Value$7.84 per share Price / Book2.02Miscellaneous Outstanding Shares24,586,000Free Float23,062,000Market Cap$389.44 million OptionableOptionable Beta-0.04 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:LYEL) was last updated on 11/12/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredA Bill Would Reprice America's Gold at Market ValueThe US government still values its gold at $42 an ounce, a price Congress set in 1973. Gold trades above $4,00...Concord Gold Capital | SponsoredMany investors are about to lose everythingTwenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a househ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lyell Immunopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lyell Immunopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LYEL Stock Alerts